BICYCLE THERAPEUTICS PLC Quarterly Operating Income (Loss) in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Bicycle Therapeutics Plc quarterly/annual Operating Income (Loss) history and growth rate from Q2 2018 to Q3 2024.
  • Bicycle Therapeutics Plc Operating Income (Loss) for the quarter ending September 30, 2024 was -$63.8M, a 25.7% decline year-over-year.
  • Bicycle Therapeutics Plc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$196M, a 17% decline year-over-year.
  • Bicycle Therapeutics Plc annual Operating Income (Loss) for 2023 was -$190M, a 62.8% decline from 2022.
  • Bicycle Therapeutics Plc annual Operating Income (Loss) for 2022 was -$117M, a 77.8% decline from 2021.
  • Bicycle Therapeutics Plc annual Operating Income (Loss) for 2021 was -$65.6M, a 26.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$196M -$63.8M -$13M -25.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 -$183M -$46.6M -$3.54M -8.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$180M -$31.7M +$10.1M +24.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 -$190M -$54.2M -$22M -68.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 -$168M -$50.8M -$21M -70.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$147M -$43.1M -$15.8M -57.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$131M -$41.8M -$14.4M -52.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 -$117M -$32.2M -$14.2M -78.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 -$102M -$29.8M -$15.5M -108% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$87M -$27.3M -$10M -58% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$77M -$27.4M -$11.4M -70.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$65.6M -$18M -$964K -5.65% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 -$64.7M -$14.3M -$3.62M -33.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$61M -$17.3M -$4.69M -37.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$56.3M -$16M -$4.38M -37.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$52M -$17.1M -$12.3M -258% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$39.7M -$10.7M -$422K -4.12% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$39.2M -$12.6M -$4.6M -57.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$34.6M -$11.6M -$8.35M -253% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$26.3M -$4.76M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$10.3M -$3.9M -61.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$7.99M -$3.03M -61.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$3.29M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q3 2018 -$6.36M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$4.96M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.